Seer Q4 2022 Earnings Report

Seer EPS Results

• Actual EPS: -$0.36
• Consensus EPS: -$0.42
• Beat/Miss: Beat by +$0.06
• One Year Ago EPS: N/A

Seer Revenue Results

• Actual Revenue: $4.60 million
• Expected Revenue: $4.64 million
• Beat/Miss: Missed by -$40.00 thousand
• YoY Revenue Growth: N/A

Seer Announcement Details

• Quarter: Q4 2022
• Date: 3/2/2023
• Time: N/A

Seer (NASDAQ:SEER), a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.